Compare Merck & Co., Inc. (MRK) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nextpower Inc. Common Stock — how do they compare? Merck & Co., Inc. trades at $149.24 (market cap $350.29B), while Nextpower Inc. Common Stock trades at $81.37 (market cap $13.47B). The key difference: Merck & Co., Inc. is far larger — about 26× Nextpower Inc. Common Stock's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Nextpower Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nextpower Inc. Common Stock for 0 Days on average.
| MRK | NXT | |
|---|---|---|
Market Cap | $350.29B | $13.47B |
Volume | 8,158,912 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $156.43 | $156.40 |
52-Week Low | $82.49 | $77.93 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $12.92B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $147.37, up 1.32% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals highlight growth momentum. Revenue reached $65.01 billion in 2025, with net income at $18.25 billion, though the P/E ratio of 113.58 reflects high valuation expectations.
Outlook is positive with a consensus price target of $158.50, but risks include patent expirations, regulatory scrutiny, and integration challenges from acquisitions. The stock's premium valuation requires sustained earnings growth to justify further upside, with investor sentiment bolstered by analyst support and strategic pipeline expansion.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
